Skip to content

Study · Randomized controlled trial · n = 5,325 · 2016

7 results

Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials.

Ard J, Cannon A, Lewis CE, Lofton H, Vang Skjøth T, Stevenin B, Pi-Sunyer X

Diabetes, obesity & metabolism11 Feb 2016Cited by 33 (Europe PMC)

PMID26744025 (opens in a new tab)PMCIDPMC6084344 (opens in a new tab)DOI10.1111/dom.12632 (opens in a new tab)PepBankPUB-26744025
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, the weight effect of liraglutide 3.0 mg versus placebo showed no dependence on race (interaction p > 0.05).

    In plain wordsIn adults with overweight or obesity, liraglutide's weight effect compared with placebo did not depend on race.

    Peptide
    Liraglutide
    Outcome
    No significant changeWeight effect by race (interaction test)
    Study

    n = 5,325

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    Treatment effects on weight and cardiovascular risk markers generally showed no dependence on race (interaction test p > 0.05).
    1 context sentence
    Summary · context
    This post hoc analysis of pooled data from five double-blind randomized, placebo-controlled trials was conducted in 5325 adults with either a body mass index (BMI) ≥27 kg/m(2) plus ≥1 comorbidity or a BMI ≥30 kg/m(2).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, the effect of liraglutide 3.0 mg versus placebo on cardiovascular risk markers showed no dependence on race (interaction p > 0.05).

    In plain wordsIn adults with overweight or obesity, liraglutide's effect on heart-risk markers compared with placebo did not depend on race.

    Peptide
    Liraglutide
    Outcome
    No significant changeCardiovascular risk marker effects by race (interaction test)
    Study

    n = 5,325

    Comparator
    Placebo
    Outcome group
    Cardiometabolic risk factors · Cardiovascular
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    Treatment effects on weight and cardiovascular risk markers generally showed no dependence on race (interaction test p > 0.05).
    1 context sentence
    Summary · context
    This post hoc analysis of pooled data from five double-blind randomized, placebo-controlled trials was conducted in 5325 adults with either a body mass index (BMI) ≥27 kg/m(2) plus ≥1 comorbidity or a BMI ≥30 kg/m(2).
  3. 03HumanRandomized controlled trialSafety outcome

    In adults with overweight or obesity, adverse events with liraglutide 3.0 mg were similar across racial subgroups.

    In plain wordsIn adults with overweight or obesity, side effects of liraglutide 3.0 mg were similar across racial groups.

    Peptide
    Liraglutide
    Outcome
    No significant changeAdverse events across racial subgroups
    Study

    n = 5,325

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    Adverse events were similar across racial subgroups.
    1 context sentence
    Summary · context
    This post hoc analysis of pooled data from five double-blind randomized, placebo-controlled trials was conducted in 5325 adults with either a body mass index (BMI) ≥27 kg/m(2) plus ≥1 comorbidity or a BMI ≥30 kg/m(2).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In white adults with overweight or obesity, liraglutide 3.0 mg gave significantly greater mean weight loss than placebo (7.7% vs 2.3%).

    In plain wordsIn white adults with overweight or obesity, liraglutide 3.0 mg led to more weight loss than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss, white subgroup
    Study

    n = 4,496

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Measurements

    Weight loss
    7.7%
    liraglutide 3.0 mg, white
    Weight loss
    2.3%
    placebo, white

    Source sentences

    Summary
    white 7.7% versus 2.3%
    1 context sentence
    Summary · context
    This post hoc analysis of pooled data from five double-blind randomized, placebo-controlled trials was conducted in 5325 adults with either a body mass index (BMI) ≥27 kg/m(2) plus ≥1 comorbidity or a BMI ≥30 kg/m(2).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In black/African-American adults with overweight or obesity, liraglutide 3.0 mg gave significantly greater mean weight loss than placebo (6.3% vs 1.4%).

    In plain wordsIn black adults with overweight or obesity, liraglutide 3.0 mg led to more weight loss than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss, black/African-American subgroup
    Study

    n = 550

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Measurements

    Weight loss
    6.3%
    liraglutide 3.0 mg, black/African-American
    Weight loss
    1.4%
    placebo, black/African-American

    Source sentences

    Summary
    black/African-American 6.3% versus 1.4%
    1 context sentence
    Summary · context
    This post hoc analysis of pooled data from five double-blind randomized, placebo-controlled trials was conducted in 5325 adults with either a body mass index (BMI) ≥27 kg/m(2) plus ≥1 comorbidity or a BMI ≥30 kg/m(2).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In Asian adults with overweight or obesity, liraglutide 3.0 mg gave significantly greater mean weight loss than placebo (6.3% vs 2.5%).

    In plain wordsIn Asian adults with overweight or obesity, liraglutide 3.0 mg led to more weight loss than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss, Asian subgroup
    Study

    n = 168

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Measurements

    Weight loss
    6.3%
    liraglutide 3.0 mg, Asian
    Weight loss
    2.5%
    placebo, Asian

    Source sentences

    Summary
    Asian 6.3% versus 2.5%
    1 context sentence
    Summary · context
    This post hoc analysis of pooled data from five double-blind randomized, placebo-controlled trials was conducted in 5325 adults with either a body mass index (BMI) ≥27 kg/m(2) plus ≥1 comorbidity or a BMI ≥30 kg/m(2).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults of other races with overweight or obesity, liraglutide 3.0 mg gave significantly greater mean weight loss than placebo (7.3% vs 0.49%).

    In plain wordsIn adults of other races with overweight or obesity, liraglutide 3.0 mg led to more weight loss than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss, other race subgroup
    Study

    n = 111

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Measurements

    Weight loss
    7.3%
    liraglutide 3.0 mg, other
    Weight loss
    0.49%
    placebo, other

    Source sentences

    Summary
    other 7.3% versus 0.49%
    1 context sentence
    Summary · context
    This post hoc analysis of pooled data from five double-blind randomized, placebo-controlled trials was conducted in 5325 adults with either a body mass index (BMI) ≥27 kg/m(2) plus ≥1 comorbidity or a BMI ≥30 kg/m(2).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01272219

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Novo Nordisk A/Sn = 3,7311 Jun 2011 to 2 Mar 2015

Metabolism and Nutrition Disorder · Obesity

Trial pageClinicalTrials.govUpdated 19 Jan 2018
CompletedPhase 3Results postedNCT01272232

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Novo Nordisk A/Sn = 8461 Jun 2011 to 25 Jan 2013

Metabolism and Nutrition Disorder · Obesity

Trial pageClinicalTrials.govUpdated 29 Dec 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.